Emerging data on androgen receptor splice variants in prostate cancer
Tóm tắt
Androgen receptor splice variants are alternatively spliced variants of androgen receptor, which are C-terminally truncated and lack the canonical ligand-binding domain. Accumulating evidence has indicated a significant role of androgen receptor splice variants in mediating resistance of castration-resistant prostate cancer to current therapies and in predicting therapeutic responses. As such, there is an urgent need to target androgen receptor splicing variants for more effective treatment of castration-resistant prostate cancer. Identification of precise and critical targeting points to deactivate androgen receptor splicing variants relies on a deep understanding of how they are generated and the mechanisms of their action. In this review, we will focus on the emerging data on their generation, clinical significance and mechanisms of action as well as the therapeutic influence of these findings.
Từ khóa
Tài liệu tham khảo
Cao, 2013, 20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor, International Journal of Cancer, 132, 1277, 10.1002/ijc.27754
Chan, 2014, Constitutive activity of the androgen receptor, Advances in Pharmacology, 70, 327, 10.1016/B978-0-12-417197-8.00011-0
Chen, 2010, Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells, Molecular Cancer, 9, 89, 10.1186/1476-4598-9-89
Kahn, 2014, Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer, International Research Journal of Biological Sciences, 10, 588, 10.7150/ijbs.8671
Karaca, 2015, Mutation of androgen receptor N-terminal phosphorylation site Tyr-267 leads to inhibition of nuclear translocation and DNA binding, PLoS ONE, 10, e0126270, 10.1371/journal.pone.0126270
Kwegyir-Afful, 2015, Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo, Oncotarget, 6, 27440, 10.18632/oncotarget.4578
Li, 2014, Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor, Journal of Medicinal Chemistry, 57, 6458, 10.1021/jm500802j
Li, 2014, Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors, Prostate, 74, 1400, 10.1002/pros.22855
Li, 2015, Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression, Oncotarget, 6, 20474, 10.18632/oncotarget.4105
Li, 2015, AR-v7 protein expression is regulated by protein kinase and phosphatase, Oncotarget, 6, 33743, 10.18632/oncotarget.5608
Liu, 2016, Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer, Oncotarget, 7, 32210, 10.18632/oncotarget.8493
Liu, 2015, MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand, Oncotarget, 6, 288, 10.18632/oncotarget.2672
Lu, 2014, The cistrome and gene signature of androgen receptor splice variants in castration-resistant prostate cancer cells, Journal of Urology, 193, 690, 10.1016/j.juro.2014.08.043
Lu, 2015, Are androgen receptor variants a substitute for the full-length receptor?, Nature Reviews Urology, 12, 137, 10.1038/nrurol.2015.13
Martin, 2015, N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy, Molecular Oncology, 9, 628, 10.1016/j.molonc.2014.10.014
Martin, 2015, Exploitation of the androgen receptor to overcome taxane resistance in advanced prostate cancer, Advances in Cancer Research, 127, 123, 10.1016/bs.acr.2015.03.001
Mellado, 2016, Diving into cabazitaxel’s mode of action: more than a taxane for the treatment of castration-resistant prostate cancer patients, Clinical Genitourinary Cancer, 14, 265, 10.1016/j.clgc.2015.12.030
Qu, 2015, Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer, Scientific Reports, 5, 7654, 10.1038/srep07654
Shafi, 2015, Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells, Oncotarget, 6, 31997, 10.18632/oncotarget.5585
Streicher, 2014, Stilbene induced inhibition of androgen receptor dimerization: implications for AR and ARDeltaLBD-signalling in human prostate cancer cells, PLoS ONE, 9, e98566, 10.1371/journal.pone.0098566
van Soest, 2013, Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer, European Journal of Cancer, 49, 3821, 10.1016/j.ejca.2013.09.026
Welti, 2016, Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer., European Urology, 70, 599, 10.1016/j.eururo.2016.03.049
Zhang, 2016, Regulation of androgen receptor splice variant AR3 by PCGEM1, Oncotarget, 7, 15481, 10.18632/oncotarget.7139